{
    "nctId": "NCT02632435",
    "briefTitle": "Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.",
    "officialTitle": "A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 56,
    "primaryOutcomeMeasure": "Accrual rates",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Histologically confirmed primary breast cancer\n* Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or; dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.\n* \u226519 years of age\n* Able to provide verbal consent\n\nExclusion Criteria\n\n\u2022 Contraindication to central line placement.",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}